Dry Eye Disease - Epidemiology Forecast

Key Highlights

In 2023, the total diagnosed prevalence of MCI in Parkinson’s disease was highest in Germany among the EU4 and the UK, accounting for nearly 995 thousand cases which is further expected to increase by 2034.
In the US, in 2023, ~6,978 thousand people were affected with Alzheimer disease, accounting for the highest number of cases in the 7MM. estimates that these numbers will increase by 2034.
In 2023, among the 7MM, the US accounted for the highest prevalent cases of MCI, representing 42% of the total cases, followed by Japan (27%), Germany (10%), and France (7%). Analysis by experts indicates that the overall diagnosed prevalent cases of MCI are expected to rise in the coming years.
As per the analyst's estimates, Japan accounted for nearly 27% of the Total Diagnosed Prevalent Cases of MCI in the 7MM in 2023.

This report delivers an in-depth understanding of Mild Cognitive Impairment, historical and forecasted epidemiology of Mild Cognitive Impairment in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan

Study Period: 2020-2034

Mild Cognitive Impairment Disease Understanding

Mild Cognitive Impairment Overview

Mild Cognitive Impairment (MCI) is a transitional stage between normal cognitive aging and dementia, characterized by noticeable cognitive decline that does not yet interfere significantly with daily functioning. Individuals with MCI experience memory issues, attention deficits, and impaired judgment, making them more vulnerable to progressing into Alzheimer’s disease or other dementias.

MCI’s growing prevalence, especially among aging populations, emphasizes the need for early detection and effective management strategies.

Mild Cognitive Impairment Diagnosis

Diagnosing MCI involves a comprehensive cognitive assessment, often including memory tests, attention evaluations, and other cognitive performance measures. Neurological exams, imaging, and biomarker analyses further confirm the condition and rule out other causes. Early diagnosis is essential, as it allows clinicians to monitor cognitive progression, assess the risk of developing dementia, and implement supportive interventions to help maintain cognitive function.

Despite advancements in MCI diagnosis, significant unmet needs persist. Challenges due to the subtlety of early symptoms, which often overlap with normal aging or other neurological conditions. Cognitive testing alone may not capture MCI’s nuanced presentation, and even with imaging or biomarkers, distinguishing MCI from early-stage dementia remains difficult. Variability in symptoms and progression further complicates diagnosis, often delaying intervention. Additionally, a lack of standardized diagnostic criteria across medical practices limits consistency, making early and accurate identification challenging.

Mild Cognitive Impairment Epidemiology

For the purpose of designing the patient-based model for the MCI epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Diagnosed Prevalent Cases of Parkinson’s Disease, Total Diagnosed Prevalent Cases of Alzheimer’s Disease, and Total Diagnosed Prevalent Cases of MCI in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.

In the assessment, the estimated total diagnosed prevalent cases of Parkinson’s disease in the US were nearly 1.21 million in 2023.
Among European countries, Germany had the highest diagnosed prevalent cases of Alzheimer’s disease with ~1,491 thousand cases, followed by France, which had diagnosed prevalent population of ~1,170 thousand in 2023. On the other hand, the UK had the lowest prevalent population (620 thousand cases).
In Japan, approximately 2.73 million diagnosed cases of MCI were identified, with around 103 thousand cases attributed to MCI due to Parkinson’s disease and 2.62 million cases due to Alzheimer’s. Projections suggest that by 2034, the prevalence of Alzheimer’s-related MCI will continue to grow and exceed that of Parkinson’s-related MCI, highlighting a trend that underscores the increasing impact of Alzheimer’s on the aging population.
The analysis shows that, among the 7MM, the US accounted highest for the total diagnosed prevalent cases of MCI. There were nearly 4.22 million diagnosed prevalent cases of MCI in the US in 2023.Projections indicate that the UK is expected to continue leading in these figures by 2034.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

The analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Boston University School of Public Health, Department of Epidemiology, US; Psychiatric Practice Bohlken, Berlin, Germany; Department of Biology, E´cole Normale Supe´rieure de Lyon, Lyon, France; Geriatric, Local Health Authority, Pistoia Italy, Department of Psychiatry, Universidad Autónoma de Madrid, Madrid, Spain; and Department of Occupational Therapy, Graduate School of Medicine, Akita University, Japan; and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of Mild Cognitive Impairment, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
A detailed review of current challenges in establishing the diagnosis.

Mild Cognitive Impairment Report Insights

Patient Population
Country-wise Epidemiology Distribution
Diagnosed prevalent cases of Parkinson’s Disease
Diagnosed Prevalent Cases of Alzheimer’s Disease
Diagnosed Prevalent Cases of MCI
Diagnosed Prevalent Cases of MCI due to Parkinson's Disease
Diagnosed Prevalent Cases of MCI due to Alzheimer’s Disease

Mild Cognitive Impairment Report Key Strengths

11 years Forecast
The 7MM Coverage
Mild Cognitive Impairment Epidemiology Segmentation

Mild Cognitive Impairment Report Assessment

Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

What are the disease risk, burdens, and unmet needs of Mild Cognitive Impairment? What will be the growth opportunities across the 7MM concerning the patient population of Mild Cognitive Impairment?
What is the historical and forecasted Mild Cognitive Impairment patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
Why is the diagnosed prevalent cases of MCI in Japan lower than the US?
Which country has a high patient share for MCI?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the Mild Cognitive Impairment prevalence cases in varying geographies over the coming years.
A detailed overview of Gender and Age Grade-specific diagnosed prevalence of MCI, along with diagnosed prevalence of MCI Based on severity of airflow limitation and diagnosed prevalence of MCI based on symptoms and exacerbation history.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Mild Cognitive Impairment Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Mild Cognitive Impairment (MCI) cases in 2023?

The highest cases of Mild Cognitive Impairment was found in the Germany among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Mild Cognitive Impairment (MCI) cases in 2023?

The highest cases of Mild Cognitive Impairment were found in the US among the 7MM in 2023.

1. Key Insights2. Report Introduction

3. Dry Eye Disease (Ded) Epidemiology Overview at a Glance

3.1. Patient Share Distribution of Ded in 2020
3.2. Patient Share Distribution of Ded in 2034

4. Epidemiology Methodology of Ded5. Executive Summary of Dry Eye Disease (Ded)6. Key Events

7. Disease Background and Overview

7.1. Introduction
7.2. Tear Film Working
7.3. Etiology
7.4. Risk Factors
7.5. Pathophysiology
7.6. Symptoms and Clinical Presentations
7.7. Diagnosis
7.7.1. Diagnostic Criteria
7.7.1.1. Comparison of Dry Eye Definition and Diagnostic Criteria Between Jdes/Ades and Dews II
7.7.1.2. Diagnostic Criteria of the Jdes, 1995 Version
7.7.1.3. Diagnostic Criteria of Ded Proposed by the Jdes (2006 Version)
7.7.2. Differential Diagnosis
7.7.3. Diagnostic Algorithm
7.7.4. Diagnostic Scheme
7.7.5. Diagnostic Guidelines
7.7.5.1. Dry Eye Syndrome Preferred Practice Pattern Guidelines by American Academy of Ophthalmology

8. Epidemiology and Patient Population

8.1. Key Findings
8.2. Assumptions and Rationale: The 7MM
8.2.1. Diagnosed Prevalence of Ded
8.2.2. Gender-Specific Prevalence of Ded
8.2.3. Age-Specific Diagnosed Prevalence of Ded
8.2.4. Severity-Specific Diagnosed Prevalence of Ded
8.3. Total Diagnosed Prevalent Cases of Ded in the 7MM
8.4. the United States
8.4.1. Total Diagnosed Prevalent Cases of Ded
8.4.2. Gender-Specific Diagnosed Prevalent Cases of Ded
8.4.3. Age-Specific Diagnosed Prevalent Cases of Ded
8.4.4. Severity-Specific Diagnosed Prevalent Cases of Ded
8.5. EU4 and the UK
8.5.1. Germany
8.5.1.1. Total Diagnosed Prevalent Cases of Ded in Germany in Germany
8.5.1.2. Gender-Specific Diagnosed Prevalent Cases of Ded in Germany
8.5.1.3. Age-Specific Diagnosed Prevalent Cases of Ded in Germany
8.5.1.4. Severity-Specific Diagnosed Prevalent Cases of Ded in Germany
8.5.2. France
8.5.2.1. Total Diagnosed Prevalent Cases of Ded in France
8.5.2.2. Gender-Specific Diagnosed Prevalent Cases of Ded in France
8.5.2.3. Age-Specific Diagnosed Prevalent Cases of Ded in France
8.5.2.4. Severity-Specific Diagnosed Prevalent Cases of Ded in France
8.5.3. Italy
8.5.3.1. Total Diagnosed Prevalent Cases of Ded in Italy
8.5.3.2. Gender-Specific Diagnosed Prevalent Cases of Ded in Italy
8.5.3.3. Age-Specific Diagnosed Prevalent Cases of Ded in Italy
8.5.3.4. Severity-Specific Diagnosed Prevalent Cases of Ded in Italy
8.5.4. Spain
8.5.4.1. Total Diagnosed Prevalent Cases of Ded in Spain
8.5.4.2. Gender-Specific Diagnosed Prevalent Cases of Ded in Spain
8.5.4.3. Age-Specific Diagnosed Prevalent Cases of Ded in Spain
8.5.4.4. Severity-Specific Diagnosed Prevalent Cases of Ded in Spain
8.5.5. the United Kingdom
8.5.5.1. Total Diagnosed Prevalent Cases of Ded in the UK
8.5.5.2. Gender-Specific Diagnosed Prevalent Cases of Ded in the UK
8.5.5.3. Age-Specific Diagnosed Prevalent Cases of Ded in the UK
8.5.5.4. Severity-Specific Diagnosed Prevalent Cases of Ded in the UK
8.6. Japan
8.6.1. Total Diagnosed Prevalent Cases of Ded
8.6.2. Gender-Specific Diagnosed Prevalent Cases of Ded
8.6.3. Age-Specific Diagnosed Prevalent Cases of Ded in the US
8.6.4. Severity-Specific Diagnosed Prevalent Cases of Ded

9. Patient Journey10. Kol Views

11. Appendix

11.1. Bibliography
11.2. Acronyms and Abbreviations
11.3. Report Methodology

12. Publisher Capabilities13. Disclaimer14. About the Publisher

List of Tables

Table 1: Summary of Epidemiology (2020-2034)
Table 2: Comparison of Juvenile Dry Eye Disease (DED) and Adult Dry Eye Disease (DED)
Table 3: Cutaneous Manifestations of Adult Dry Eye Disease (DED)
Table 4: Systemic Manifestations of Dry Eye Disease (DED) in Adults and Children
Table 5: Bohan and Peter Classification Criteria for Polymyositis and Dry Eye Disease (DED)
Table 6: Diagnostic Criteria for Dry Eye Disease (DED)
Table 7: The European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile IIM
Table 8: Currently Used ‘Guidance for Diagnosis in Specified Pediatric Chronic Diseases
Table 9: Recommendations Regarding Diagnosis
Table 10: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the 7MM (2020-2034)
Table 11: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Table 12: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Table 13: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Table 14: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Table 15: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Table 16: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Table 17: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Table 18: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Table 19: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Table 20: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Table 21: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Table 22: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Table 23: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Table 24: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Table 25: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Table 26: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Table 27: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Table 28: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Table 29: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Table 30: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Table 31: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Table 32: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Table 33: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Table 34: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Table 35: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Table 36: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Table 37: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Table 38: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Table 39: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Table 40: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Table 41: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Table 42: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Table 43: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Table 44: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Table 45: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Table 46: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Table 47: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Table 48: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Table 49: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Table 50: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Table 51: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Table 52: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Table 53: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
Table 54: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
Table 55: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
Table 56: Severity-specific Diagnosed Prevalent cases of Dry Eye Disease (DED) in Japan (2020-2034)
Table 57: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
Table 58: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)

List of Figures

Figure 1: Signs and Symptoms of Dry Eye Disease (DED)
Figure 2: Contributing Factors to Dry Eye Disease (DED)
Figure 3: Causes of Dry Eye Disease (DED)
Figure 4: Complications Associated With Dry Eye Disease (DED)
Figure 5: The Vicious Pro-inflammatory Circle in Dry Eye Disease (DED)
Figure 6: Classification Tree for a Subtype of IIM
Figure 7: Patient Journey of Dry Eye Disease (DED)
Figure 8: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the 7MM (2020-2034)
Figure 9: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Figure 10: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Figure 11: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Figure 12: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Figure 13: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Figure 14: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Figure 15: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Figure 16: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Figure 17: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Figure 18: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Figure 19: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Figure 20: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Figure 21: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Figure 22: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Figure 23: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Figure 24: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Figure 25: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Figure 26: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Figure 27: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Figure 28: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Figure 29: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Figure 30: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Figure 31: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Figure 32: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Figure 33: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Figure 34: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Figure 35: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Figure 36: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Figure 37: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Figure 38: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Figure 39: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Figure 40: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Figure 41: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Figure 42: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Figure 43: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Figure 44: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Figure 45: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Figure 46: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Figure 47: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Figure 48: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Figure 49: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Figure 50: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Figure 51: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
Figure 52: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
Figure 53: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
Figure 54: Severity-specific Diagnosed Prevalent cases of Dry Eye Disease (DED) in Japan (2020-2034)
Figure 55: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
Figure 56: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
Figure 57: Patient Journey

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2730EUR$2,765USD£2,280GBP €3900EUR$3,950USD£3,257GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€4680EUR$4,740USD£3,908GBP €7801EUR$7,900USD£6,514GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€9361EUR$9,480USD£7,817GBP €11701EUR$11,850USD£9,771GBP

Dry Eye Disease - Epidemiology Forecast - 2034

Key Highlights

Geography Covered

Study Period: 2020-2034

Mild Cognitive Impairment Disease Understanding

Mild Cognitive Impairment Overview

Mild Cognitive Impairment Diagnosis

Mild Cognitive Impairment Epidemiology

KOL Views

Scope of the Report

Mild Cognitive Impairment Report Insights

Mild Cognitive Impairment Report Key Strengths

Mild Cognitive Impairment Report Assessment

Epidemiology Insights

Reasons to Buy

Frequently Asked Questions

1. What is the forecast period covered in the report?

2. Out of all EU4 countries and the UK, which country had the highest population of Mild Cognitive Impairment (MCI) cases in 2023?

3. How is epidemiological data collected and analyzed for forecasting purposes?

4. Out of all 7MM countries, which country had the highest population of Mild Cognitive Impairment (MCI) cases in 2023?

Table of Contents

Key Highlights

Geography Covered

Study Period: 2020-2034

Mild Cognitive Impairment Disease Understanding

Mild Cognitive Impairment Overview

Mild Cognitive Impairment Diagnosis

Mild Cognitive Impairment Epidemiology

KOL Views

Scope of the Report

Mild Cognitive Impairment Report Insights

Mild Cognitive Impairment Report Key Strengths

Mild Cognitive Impairment Report Assessment

Epidemiology Insights

Reasons to Buy

Frequently Asked Questions

1. What is the forecast period covered in the report?

2. Out of all EU4 countries and the UK, which country had the highest population of Mild Cognitive Impairment (MCI) cases in 2023?

3. How is epidemiological data collected and analyzed for forecasting purposes?

4. Out of all 7MM countries, which country had the highest population of Mild Cognitive Impairment (MCI) cases in 2023?

Table of Contents

Related Topics

Related Reports

Dry Eye Syndrome Market Report by Disease Type, Drug Type, Product, Distribution Channel, and Region 2024-2032

Dry Eye Syndrome Treatment Market Size, Share and Trends Analysis Report by Type (Evaporative, Aqueous Deficient), Drug, Product, Dosage Form, Sales Channel, Distribution Channel, and Region 2024-2030

Dry Eye Medication Market Report 2024

Dry Eye Syndrome Market by Drug, Product - Global Forecast 2025-2030

Dry Eye Syndrome Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application